High Sensitivity Octet® BLI platform Covers Molecular Binding Interactions Range From Virus Particle to Small Molecule
Sartorius Octet® BLI platform offers unprecedent technology whose the flexibility of the experimental set-up design enables to analyze a large panel of molecular interactions. From virus particle to small molecule by way of glycoprotein, DNA, bioconjugate, antibody fragment, peptide, bispecific antibody, multispecific scaffold, enzyme, glycan and even embedded protein in lipid bilayer. Octet® BLI sensititvity makes these binding interactions range measurables.
Even though target and compound can either be used in solution or immobilized on the biosensors; proteins stability, binding partners size, motif accessibility, tag presence and valency are primary concerns when choosing orientation. Nevertheless during library screening campaign target is usually the ligand, whereas for binding kinetic assays target can be used either as a ligand or an analyte.
Drug Diversity for BLI Applications
Molecular Diversity and Interaction Matrix of Binding Partners
Membrane proteins roles are crucial through multiple cellular functions. These represent the largest class of pharmaceutical drug targets (e.g GPCR, neurotransmitter receptor, ion channels, viral protein…), making them critical tool in the characterization of drug candidates.
Molecular interactions with membrane proteins are challenging and more difficult to characterize than soluble protein due to their integration into lipid bilayer. To preserve native structural integrity and solubility, membrane proteins can be embedded in their biologically relevant conformations within lipidic bilayer particle such as liposomes, virus-like particles (VLP), nanodiscs, exosome or after solubilization in detergent environments. Besides, virus particles have emerged as promising antigen delivery platform for vaccine development.
Octet® BLI system offers possibilities to measure binding interactions between embedded target in particles and drug candidate. The target integrity minimizes later-phase failures caused by non-expected or loss binding characteristics.
Overall, BLI platform covers an exceptionally wide range of targets molecular size (from small molecule to nanoparticle) that can be used for detection, quantitation, and kinetic applications throughout drug and vaccine research and development processes.
Target Diversity for BLI Applications
